Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.

Bauss F, Lechmann M, Krippendorff BF, Staack R, Herting F, Festag M, Imhof-Jung S, Hesse F, Pompiati M, Kollmorgen G, da Silva Mateus Seidl R, Bossenmaier B, Lau W, Schantz C, Stracke JO, Brinkmann U, Onda M, Pastan I, Bosslet K, Niederfellner G.

Mol Oncol. 2016 Oct;10(8):1317-29. doi: 10.1016/j.molonc.2016.07.003. Epub 2016 Jul 14.

2.

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.

Brünker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, Weiser B, Majety M, Runza V, Niu H, Packman K, Feng N, Daouti S, Hosse RJ, Mössner E, Weber TG, Herting F, Scheuer W, Sade H, Shao C, Liu B, Wang P, Xu G, Vega-Harring S, Klein C, Bosslet K, Umaña P.

Mol Cancer Ther. 2016 May;15(5):946-57. doi: 10.1158/1535-7163.MCT-15-0647. Epub 2016 Apr 1.

3.

Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers.

Alewine C, Xiang L, Yamori T, Niederfellner G, Bosslet K, Pastan I.

Mol Cancer Ther. 2014 Nov;13(11):2653-61. doi: 10.1158/1535-7163.MCT-14-0132. Epub 2014 Sep 19.

4.

Expression of CD66 in non-Hodgkin lymphomas and multiple myeloma.

Guinn BA, Bosslet K, Lee C, Richardson D, Orchard K.

Eur J Haematol. 2011 Dec;87(6):554-5. doi: 10.1111/j.1600-0609.2011.01698.x. Epub 2011 Oct 2. No abstract available.

PMID:
21883478
5.

Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.

Gao J, Chesebrough JW, Cartlidge SA, Ricketts SA, Incognito L, Veldman-Jones M, Blakey DC, Tabrizi M, Jallal B, Trail PA, Coats S, Bosslet K, Chang YS.

Cancer Res. 2011 Feb 1;71(3):1029-40. doi: 10.1158/0008-5472.CAN-10-2274. Epub 2011 Jan 18.

6.

Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709.

Siemeister G, Luecking U, Wagner C, Detjen K, Mc Coy C, Bosslet K.

Biomed Pharmacother. 2006 Jul;60(6):269-72. Epub 2006 Jun 23.

PMID:
16887322
7.

Dose optimization of a doxorubicin prodrug (HMR 1826) in isolated perfused human lungs: low tumor pH promotes prodrug activation by beta-glucuronidase.

Mürdter TE, Friedel G, Backman JT, McClellan M, Schick M, Gerken M, Bosslet K, Fritz P, Toomes H, Kroemer HK, Sperker B.

J Pharmacol Exp Ther. 2002 Apr;301(1):223-8.

PMID:
11907177
8.

Immunohistochemically visualized localisation of gangliosides Glac2 (GD3) and Gtri2 (GD2) in cells of human intracranial tumors.

Mennel HD, Bosslet K, Geissel H, Bauer BL.

Exp Toxicol Pathol. 2000 Aug;52(4):277-85.

PMID:
10987178
9.

Synthesis and cytotoxic activity of a glucuronylated prodrug of nornitrogen mustard.

Papot S, Combaud D, Bosslet K, Gerken M, Czech J, Gesson JP.

Bioorg Med Chem Lett. 2000 Aug 21;10(16):1835-7.

PMID:
10969980
10.

Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy.

Desbene S, Van HD, Michel S, Tillequin F, Koch M, Schmidt F, Florent JC, Monneret C, Straub R, Czech J, Gerken M, Bosslet K.

Anticancer Drug Des. 1999 Apr;14(2):93-106.

PMID:
10405636
11.

Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.

Florent JC, Dong X, Gaudel G, Mitaku S, Monneret C, Gesson JP, Jacquesy JC, Mondon M, Renoux B, Andrianomenjanahary S, Michel S, Koch M, Tillequin F, Gerken M, Czech J, Straub R, Bosslet K.

J Med Chem. 1998 Sep 10;41(19):3572-81.

PMID:
9733483
12.

Simultaneous high-performance liquid chromatographic determination of a glucuronyl prodrug of doxorubicin, doxorubicin and its metabolites in human lung tissue.

Mürdter TE, Sperker B, Bosslet K, Fritz P, Kroemer HK.

J Chromatogr B Biomed Sci Appl. 1998 May 29;709(2):289-95.

PMID:
9657226
13.

Elucidation of the mechanism enabling tumor selective prodrug monotherapy.

Bosslet K, Straub R, Blumrich M, Czech J, Gerken M, Sperker B, Kroemer HK, Gesson JP, Koch M, Monneret C.

Cancer Res. 1998 Mar 15;58(6):1195-201.

14.

Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site.

Mürdter TE, Sperker B, Kivistö KT, McClellan M, Fritz P, Friedel G, Linder A, Bosslet K, Toomes H, Dierkesmann R, Kroemer HK.

Cancer Res. 1997 Jun 15;57(12):2440-5.

15.

Interindividual variability in expression and activity of human beta-glucuronidase in liver and kidney: consequences for drug metabolism.

Sperker B, Mürdter TE, Schick M, Eckhardt K, Bosslet K, Kroemer HK.

J Pharmacol Exp Ther. 1997 May;281(2):914-20.

PMID:
9152401
17.

Prodrugs of anthracycline antibiotics suited for tumor-specific activation.

Azoulay M, Florent JC, Monneret C, Gesson JP, Jacquesy JC, Tillequin F, Koch M, Bosslet K, Czech J, Hoffman D.

Anticancer Drug Des. 1995 Sep;10(6):441-50.

PMID:
7575986
18.

8th International AEK symposium of the Division of Experimental Cancer Research of the German Cancer Society. 29-31 March 1995, Heidelberg, Germany.

Rabes HM, Gabbert HE, Grunicke H, Lutz WK, Bornkamm G, Brandner G, Bosslet K, Rajewsky MF, Eisenbrand G, Schneider MR, et al.

J Cancer Res Clin Oncol. 1995;121(11):683-90. No abstract available.

PMID:
7593133
19.

Biochemical properties of recombinant human beta-glucuronidase synthesized in baby hamster kidney cells.

Gehrmann MC, Opper M, Sedlacek HH, Bosslet K, Czech J.

Biochem J. 1994 Aug 1;301 ( Pt 3):821-8.

20.

Tumor-selective prodrug activation by fusion protein-mediated catalysis.

Bosslet K, Czech J, Hoffmann D.

Cancer Res. 1994 Apr 15;54(8):2151-9.

21.

Fusion protein mediated prodrug activation (FMPA) in vivo.

Bosslet K, Czech J, Seemann G, Monneret C, Hoffmann D.

Cell Biophys. 1994;24-25:51-63.

PMID:
7736540
22.

Monoclonal antibody BW494 defines a blood group Lewisa/type 1 chain-related antigen on carcinoma-associated mucins.

Hanisch FG, Auerbach B, Bosslet K, Kolbe K, Karsten U, Nakahara Y, Ogawa T, Uhlenbruck G.

Biol Chem Hoppe Seyler. 1993 Dec;374(12):1083-91.

PMID:
7510494
23.

CA 494--a new tumor marker for the diagnosis of pancreatic cancer.

Friess H, Büchler M, Auerbach B, Weber A, Malfertheiner P, Hammer K, Madry N, Greiner S, Bosslet K, Beger HG.

Int J Cancer. 1993 Mar 12;53(5):759-63.

PMID:
8449599
24.

Characterisation of a humanised bispecific monoclonal antibody for cancer therapy.

Bruynck A, Seemann G, Bosslet K.

Br J Cancer. 1993 Mar;67(3):436-40.

25.

Humanized anti-carcinoembryonic antigen antibody: strategies to enhance human tumor cell killing.

Kaulen H, Seemann G, Bosslet K, Schwaeble W, Dippold W.

Year Immunol. 1993;7:106-9. No abstract available.

PMID:
8372499
26.

Expression of GD2-epitopes in human intracranial tumors and normal brain.

Mennel HD, Bosslet K, Wiegandt H, Sedlacek HH, Bauer BL, Rodden AF.

Exp Toxicol Pathol. 1992 Oct;44(6):317-24.

PMID:
1280497
28.

Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation.

Bosslet K, Czech J, Lorenz P, Sedlacek HH, Schuermann M, Seemann G.

Br J Cancer. 1992 Feb;65(2):234-8.

29.

Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy.

Bosslet K, Steinstraesser A, Hermentin P, Kuhlmann L, Bruynck A, Magerstaedt M, Seemann G, Schwarz A, Sedlacek HH.

Br J Cancer. 1991 May;63(5):681-6.

30.

Percolation and binding of MAB BW 494 to pancreatic carcinoma tissues during high dose immunotherapy and consequences for future therapy modalities.

Bosslet K, Keweloh HC, Hermentin P, Muhrer KH, Sedlacek HH, Schulz G.

Behring Inst Mitt. 1990 Dec;(87):68-75.

PMID:
2096821
31.

Recombinant monoclonal antibodies in tumor therapy.

Seemann G, Bosslet K, Sedlacek HH.

Behring Inst Mitt. 1990 Dec;(87):33-47. Review.

PMID:
2096819
32.

Two-phase radioimmunotherapy using bispecific monoclonal antibodies (bs MAbs).

Bosslet K, Hermentin P, Kuhlmann L, Steinstraesser A, Seemann G, Sedlacek HH.

Cancer Treat Rev. 1990 Sep;17(2-3):355-6. No abstract available.

PMID:
2272051
33.
34.

Attachment of rhodosaminylanthracyclinone-type anthracyclines to the hinge region of monoclonal antibodies.

Hermentin P, Doenges R, Gronski P, Bosslet K, Kraemer HP, Hoffmann D, Zilg H, Steinstraesser A, Schwarz A, Kuhlmann L, et al.

Bioconjug Chem. 1990 Mar-Apr;1(2):100-7.

PMID:
2095207
35.

In vivo labelling of thrombocytes with the monoclonal antibody Tc-99m-BW4 for imaging phlebothrombosis.

Höffken H, Joseph K, Beer R, Geraetz P, Bosslet K, Schorlemmer HU, Schwarz A.

Prog Clin Biol Res. 1990;355:343-9. No abstract available.

PMID:
2281112
36.

Preclinical and clinical testing of radiolabelled monoclonal antibodies for immunoscintigraphy.

Steinsträsser A, Schwarz A, Kuhlmann L, Seidel L, Niemann E, Bosslet K.

Dev Biol Stand. 1990;71:137-45. Review.

PMID:
2205523
37.

Removal of neuroblastoma cells from bone marrow by a direct monoclonal antibody rosetting technique.

Berthold F, Schumacher R, Schneider A, Bosslet K, Reiter C.

Bone Marrow Transplant. 1989 May;4(3):273-8.

PMID:
2659112
38.

Detection of minimal disease in bone marrow of neuroblastoma patients by immunofluorescence.

Berthold F, Schneider A, Schumacher R, Bosslet K.

Pediatr Hematol Oncol. 1989;6(2):73-83.

PMID:
2702075
39.

Monoclonal antibodies against epitopes on ganglioside GD2 and its lactones. Markers for gliomas and neuroblastomas.

Bosslet K, Mennel HD, Rodden F, Bauer BL, Wagner F, Altmannsberger A, Sedlacek HH, Wiegandt H.

Cancer Immunol Immunother. 1989;29(3):171-8.

PMID:
2471592
40.

Imaging of inflammation with granulocytes labelled in vivo.

Joseph K, Höffken H, Bosslet K, Schorlemmer HU.

Nucl Med Commun. 1988 Oct;9(10):763-9.

PMID:
3211435
41.

[Immunoscintigraphy of colorectal cancers and specific immunotherapy of pancreatic cancers using monoclonal antibodies].

Bosslet K, Schwarz A, Steinstraesser A, Kuhlmann L, Seidel L, Schulz G.

Wien Med Wochenschr. 1988 Jun 30;138(11-12):255-7. German.

PMID:
3262953
42.

Similarities in function between pancreatic tumor cells and macrophages and their inhibition by murine monoclonal antibodies.

Schorlemmer HU, Bosslet K, Kern HF, Sedlacek HH.

Behring Inst Mitt. 1988 Apr;(82):240-64.

PMID:
3408453
43.

Human monoclonal anti-idiotypic antibodies as an epitope vaccine against pancreatic carcinoma.

Bosslet K, Büchler M, Klapdor R, Muhrer C, Sedlacek HH, Schulz G.

Behring Inst Mitt. 1988 Apr;(82):193-6.

PMID:
3261582
45.

[Immunotherapy of advanced pancreatic carcinoma with the monoclonal antibody BW 494].

Büchler M, Kübel R, Malfertheiner P, Friess H, Schulz G, Bosslet K, Beger HG.

Dtsch Med Wochenschr. 1988 Mar 11;113(10):374-80. German.

PMID:
3349938
46.

In vivo labelling of granulocytes with 99mTc anti-NCA monoclonal antibodies for imaging inflammation.

Joseph K, Höffken H, Bosslet K, Schorlemmer HU.

Eur J Nucl Med. 1988;14(7-8):367-73.

PMID:
3181186
47.

Characterization of a colon carcinoma cell line for tumor immunotherapy.

Bosslet K, Sedlacek HH.

Cancer Detect Prev. 1988;12(1-6):461-7.

PMID:
3180140
48.

Immunotherapy of pancreatic cancer with monoclonal antibody BW 494.

Schulz G, Büchler M, Muhrer KH, Klapdor R, Kübel R, Harthus HP, Madry N, Bosslet K.

Int J Cancer Suppl. 1988;2:89-94.

PMID:
3162451
49.

Immunological tailoring of monoclonal antibodies for immunotherapy of pancreatic carcinoma.

Bosslet K, Döring N, Seemann G, Schulz G, Sedlacek HH.

Int J Cancer Suppl. 1988;2:85-8.

PMID:
3162450
50.

Quantitative considerations supporting the irrelevance of circulating serum CEA for the immunoscintigraphic visualization of CEA expressing carcinomas.

Bosslet K, Steinsträsser A, Schwarz A, Harthus HP, Lüben G, Kuhlmann L, Sedlacek HH.

Eur J Nucl Med. 1988;14(11):523-8.

PMID:
2463168

Supplemental Content

Loading ...
Support Center